Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis

  • Technology appraisal guidance
  • TA624
  • Published: 
Download guidance (PDF)

2 Information about peginterferon beta-1a

Marketing authorisation indication

2.1 Peginterferon beta‑1a (Plegridy, Biogen Idec Ltd) has been licensed since 2014 'in adult patients for the treatment of relapsing remitting multiple sclerosis'.

Dosage in the marketing authorisation

2.2 Peginterferon beta‑1a is given by subcutaneous injection every 2 weeks at a dose of 125 micrograms.

Price

2.3 The list price for peginterferon beta‑1a is £654.00 per 2 pre-filled pens, each containing 125 micrograms (excluding VAT, BNF online, November 2019). Costs may vary in different settings because of negotiated procurement discounts.